Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid leukemia (CML),
but some patients do not respond and many responses are not durable. To improve the …

Background Treatment with interferon prolongs survival in chronic myelogenous leukemia.
We conducted a clinical trial to assess the efficacy of treatment with a combination of …

PURPOSE: To provide a status report on the use of interferon (IFN)-a in patients with chronic
myelogenous leukemia (CML). DATA SOURCES: Data on IFN-a therapy for CML collected …

Interferon-alfa (IFNα) became the first-line agent for the treatment of chronic myeloid
leukemia (CML) because it prolongs survival significantly compared to conventional …

Background In view of studies showing that interferon alfa was effective treatment for chronic
myeloid leukemia and that it prolonged survival, we organized a prospective, controlled …

PURPOSE To evaluate the efficacy of interferon-alpha (IFN-A) and low-dose cytarabine (ara-
C) combination chemotherapy in patients with chronic myelogenous leukemia (CML) …

131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia
(CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN …

Background: Several randomized clinical trials in chronic myeloid leukemia (CML) have
reported better patient survival with interferon alfa (IFN α) than with standard …

Several prospective randomized studies have shown that the treatment of chronic myeloid
leukemia with interferon-(IFN-) prolongs the survival by comparison with conventional …

Treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-α) was introduced
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …